Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 6/20 | 0.35 |
| ▸ | FLT1 | P17948 | 4/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746686 | 1.00 | NUDT1 (0.43) | NUDT1KMT2ACNR2TRPM5MAP2K1 | |
| SCHEMBL30746436 | 0.88 | NUDT1 (0.40) | NUDT1KMT2ACNR2TRPM5KDR | |
| SCHEMBL26985312 | 0.88 | NUDT1 (0.40) | NUDT1KMT2ACNR2TRPM5KDR | |
| SCHEMBL26985139 | 0.82 | NUDT1 (0.47) | NUDT1KMT2ATRPM5MAP2K1KDR | |
| SCHEMBL30746528 | 0.82 | NUDT1 (0.47) | NUDT1KMT2ATRPM5MAP2K1KDR | |
| SCHEMBL26985321 | 0.79 | NUDT1 (0.53) | NUDT1KMT2ACNR2MAP2K1CSF1R | |
| SCHEMBL30746391 | 0.79 | NUDT1 (0.53) | NUDT1KMT2ACNR2MAP2K1CSF1R | |
| SCHEMBL30746627 | 0.78 | NUDT1 (0.39) | NUDT1KMT2ACNR2TRPM5MAP2K1 | |
| SCHEMBL26985082 | 0.78 | NUDT1 (0.39) | NUDT1KMT2ACNR2TRPM5MAP2K1 | |
| SCHEMBL30746560 | 0.76 | NUDT1 (0.53) | NUDT1CNR2MAP2K1KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4551558-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | NUDT1 1810/4885KMT2A 1855/4885CNR2 155/4885 |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | BRAF, MAP3K1, MAP3K5 | NUDT1 2559/4885KMT2A 1441/4885CNR2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.